Newsroom 2006

Attention Business/Financial Editors:

Neurochem to Present at Upcoming Healthcare Conferences

LAVAL, QC, Nov. 3 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Monday, November 6, 2006, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem's overall strategy and progress to date at the Rodman & Renshaw 8th Annual Healthcare Conference to be held at the New York Palace Hotel, in New York (N.Y.). The presentation will take place at 9:10 A.M. ET, in room Holmes II.
The corporate presentation will be available on the Company's Web site at http://www.neurochem.com/Investor.htm#Presentation following Dr. Bellini's speech.
Dr. Bellini will also present an update on the Company's activities at the CIBC 17th Annual Healthcare Conference on Monday, November 6, 2006, at the Waldorf-Astoria in New York (N.Y.). The presentation will take place at 3:15 P.M. ET, in the Jade room, and will be available on the Company's website.

About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration and European Medicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, is currently in Phase III clinical trials in both North America and Europe and tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at www.neurochem.com.

Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may
constitute forward-looking statements. Such statements, based as they are
on the current expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
Neurochem's control. Such risks include but are not limited to: the
impact of general economic conditions, general conditions in the
pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility,
fluctuations in costs, and changes to the competitive environment due to
consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance, if any, on the forward-looking
statements included in this news release. These statements speak only as
of the date made and Neurochem is under no obligation and disavows any
intention to update or revise such statements as a result of any event,
circumstances or otherwise. Please see the Annual Information Form for
further risk factors that might affect the Company and its business.

For further information: Lise Hébert, PhD, Vice President, Corporate Communications, (450) 680-4570, lhebert@neurochem.com